The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future

Overview

Journal Neuropsychopharmacology

Date 2017 Apr 27

PMID 28443617

Citations 173

Authors

Robin L Carhart-Harris

Guy M Goodwin

Affiliations

Soon will be listed here.

Abstract

Plant-based psychedelics, such as psilocybin, have an ancient history of medicinal use. After the first English language report on LSD in 1950, psychedelics enjoyed a short-lived relationship with psychology and psychiatry. Used most notably as aids to psychotherapy for the treatment of mood disorders and alcohol dependence, drugs such as LSD showed initial therapeutic promise before prohibitive legislature in the mid-1960s effectively ended all major psychedelic research programs. Since the early 1990s, there has been a steady revival of human psychedelic research: last year saw reports on the first modern brain imaging study with LSD and three separate clinical trials of psilocybin for depressive symptoms. In this circumspective piece, RLC-H and GMG share their opinions on the promises and pitfalls of renewed psychedelic research, with a focus on the development of psilocybin as a treatment for depression.

Citing Articles

The Therapeutic Potential of Psychedelics on Reducing Rumination: A Mini-Review.

Ramarushton B, Blumenthal H, Ryals A, Boals A, Thompson L Psychedelic Med (New Rochelle). 2025; 2(3):146-152.

PMID: 40051683 PMC: 11658672. DOI: 10.1089/psymed.2024.0009.

Examining the Rationale for Studying Psychedelic-Assisted Psychotherapy for the Treatment of Caregiver Distress.

Gold N, Podrebarac S, White L, Marini C, Simon N, Mittelman M Psychedelic Med (New Rochelle). 2025; 1(2):87-97.

PMID: 40046728 PMC: 11658675. DOI: 10.1089/psymed.2022.0011.

Training the embodied self in its impermanence: meditators evidence neurophysiological markers of death acceptance.

Dor-Ziderman Y, Schweitzer Y, Nave O, Trautwein F, Fulder S, Lutz A Neurosci Conscious. 2025; 2025(1):niaf002.

PMID: 40041745 PMC: 11879107. DOI: 10.1093/nc/niaf002.

Artificial intelligence in drug development: reshaping the therapeutic landscape.

Niazi S, Mariam Z Ther Adv Drug Saf. 2025; 16:20420986251321704.

PMID: 40008227 PMC: 11851753. DOI: 10.1177/20420986251321704.

The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical Trials.

Hogea L, Tabugan D, Costea I, Albai O, Nussbaum L, Cojocaru A Medicina (Kaunas). 2025; 61(2).

PMID: 40005395 PMC: 11857248. DOI: 10.3390/medicina61020278.

References

Jokela M, Keltikangas-Jarvinen L, Kivimaki M, Puttonen S, Elovainio M, Rontu R . Serotonin receptor 2A gene and the influence of childhood maternal nurturance on adulthood depressive symptoms. Arch Gen Psychiatry. 2007; 64(3):356-60. DOI: 10.1001/archpsyc.64.3.356. View

Daumann J, Wagner D, Heekeren K, Neukirch A, Thiel C, Gouzoulis-Mayfrank E . Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis. J Psychopharmacol. 2009; 24(10):1515-24. DOI: 10.1177/0269881109103227. View

Grob C, Danforth A, Chopra G, Hagerty M, McKay C, Halberstadt A . Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2010; 68(1):71-8. DOI: 10.1001/archgenpsychiatry.2010.116. View

Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller K, Vollenweider F . Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects. Biol Psychiatry. 2015; 78(8):544-53. DOI: 10.1016/j.biopsych.2014.11.015. View

Belsky J . The Differential Susceptibility Hypothesis: Sensitivity to the Environment for Better and for Worse. JAMA Pediatr. 2016; 170(4):321-2. DOI: 10.1001/jamapediatrics.2015.4263. View

Johnson M, Richards W, Griffiths R . Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008; 22(6):603-20. PMC: 3056407. DOI: 10.1177/0269881108093587. View

Carhart-Harris R, Nutt D . Experienced drug users assess the relative harms and benefits of drugs: a web-based survey. J Psychoactive Drugs. 2014; 45(4):322-8. DOI: 10.1080/02791072.2013.825034. View

Griffiths R, Johnson M, Carducci M, Umbricht A, Richards W, Richards B . Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016; 30(12):1181-1197. PMC: 5367557. DOI: 10.1177/0269881116675513. View

Sackeim H . The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001; 62 Suppl 16:10-7. View

10.

Hermle L, Funfgeld M, Oepen G, Botsch H, Borchardt D, Gouzoulis E . Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. Biol Psychiatry. 1992; 32(11):976-91. DOI: 10.1016/0006-3223(92)90059-9. View

11.

McCabe C, Mishor Z, Cowen P, Harmer C . Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Biol Psychiatry. 2009; 67(5):439-45. PMC: 2828549. DOI: 10.1016/j.biopsych.2009.11.001. View

12.

Cohen S . Lysergic acid diethylamide: side effects and complications. J Nerv Ment Dis. 1960; 130:30-40. DOI: 10.1097/00005053-196001000-00005. View

13.

Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T . Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014; 202(7):513-20. PMC: 4086777. DOI: 10.1097/NMD.0000000000000113. View

14.

Sharpe M, Strong V, Allen K, Rush R, Postma K, Tulloh A . Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs. Br J Cancer. 2004; 90(2):314-20. PMC: 2409546. DOI: 10.1038/sj.bjc.6601578. View

15.

Riba J, Anderer P, Jane F, Saletu B, Barbanoj M . Effects of the South American psychoactive beverage ayahuasca on regional brain electrical activity in humans: a functional neuroimaging study using low-resolution electromagnetic tomography. Neuropsychobiology. 2004; 50(1):89-101. DOI: 10.1159/000077946. View

16.

Oram M . Efficacy and enlightenment: LSD psychotherapy and the Drug Amendments of 1962. J Hist Med Allied Sci. 2012; 69(2):221-50. DOI: 10.1093/jhmas/jrs050. View

17.

Bradley P, Elkes C, Elkes J . On some effects of lysergic acid diethylamide (L.S.D. 25) in normal volunteers. J Physiol. 1953; 121(2):50P-51P. View

18.

Carhart-Harris R, Muthukumaraswamy S, Roseman L, Kaelen M, Droog W, Murphy K . Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci U S A. 2016; 113(17):4853-8. PMC: 4855588. DOI: 10.1073/pnas.1518377113. View

19.

Riba J, Romero S, Grasa E, Mena E, Carrio I, Barbanoj M . Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant. Psychopharmacology (Berl). 2006; 186(1):93-8. DOI: 10.1007/s00213-006-0358-7. View

20.

Kometer M, Schmidt A, Bachmann R, Studerus E, Seifritz E, Vollenweider F . Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry. 2012; 72(11):898-906. DOI: 10.1016/j.biopsych.2012.04.005. View